Novartis to commercialise Cepheid's leukaemia test
This article was originally published in Clinica
Executive Summary
Novartis is to fund clinical development of Cepheid’s test for monitoring blood specimens from patients with Philadelphia chromosome-positive chronic myelogenous leukaemia (CML).